Hiroshi Kikukawa

Dr. Hiroshi Kikukawa

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2021 in Marine Drugs
Verified
Journal Article
Open access
PDF file
HKHiroshi Kikukawa
Hiroshi Kikukawa
TOTakuma Okaya
Takuma Okaya
TMTakashi Maoka
Takashi Maoka
MMMasayuki Miyazaki
Masayuki Miyazaki
KMKeita Murofushi
Keita Murofushi
KHKiyotaka Hara
Kiyotaka Hara
Carotenoids are used commercially for dietary supplements, cosmetics, and pharmaceuticals because of their antioxidant activity. In this study, colored microorganisms were isolated from deep sea sediment that had been collected from Suruga Bay, Shizuoka, Japan. One strain was found to be a pure yellow carotenoid producer, and the strain was identified as Sphingomonas sp. (Proteobacteria) by 16S rRNA gene sequence analysis; members of this genus are commonly isolated from air, the human body, and marine environments. The carotenoid was identified as nostoxanthin ((2,3,2′,3′)-β,β-carotene-2,3,2′,3′-tetrol) by mass spectrometry (MS), MS/MS, and ultraviolet-visible absorption spectroscopy (UV-Vis). Nostoxanthin is a poly-hydroxy yellow carotenoid isolated from some photosynthetic bacteria, including some species of Cyanobacteria. The strain Sphingomonas sp. SG73 produced highly pure nostoxanthin of approximately 97% (area%) of the total carotenoid production, and the strain was halophilic and tolerant to 1.5-fold higher salt concentration as compared with seawater. When grown in 1.8% artificial sea salt, nostoxanthin production increased by 2.5-fold as compared with production without artificial sea salt. These results indicate that Sphingomonas sp. SG73 is an efficient producer of nostoxanthin, and the strain is ideal for carotenoid production using marine water because of its compatibility with sea salt.

26 March 2022 in Metabolic Engineering
Verified
Journal Article
Closed access
YTYoshihiro Toya
Yoshihiro Toya
YHYoko Hirono-Hara
Yoko Hirono-Hara
HHHidenobu Hirayama
Hidenobu Hirayama
KKKentaro Kamata
Kentaro Kamata
RTRyo Tanaka
Ryo Tanaka
KHKiyotaka Hara
Kiyotaka Hara

21 October 2020 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
KHKiyotaka Hara
Kiyotaka Hara
YKYuya Kageyama
Yuya Kageyama
NTNanami Tanzawa
Nanami Tanzawa
YHYoko Hirono-Hara
Yoko Hirono-Hara
HKHiroshi Kikukawa
Hiroshi Kikukawa
KWKeiji Wakabayashi
Keiji Wakabayashi

1 August 2021 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Closed access
HKHiroshi Kikukawa
Hiroshi Kikukawa
CSChisato Shimizu
Chisato Shimizu
YHYoko Hirono-Hara
Yoko Hirono-Hara
KHKiyotaka Y. Hara
Kiyotaka Y. Hara

16 August 2021 in Marine Drugs
Verified
Journal Article
Open access
PDF file
KHKiyotaka Hara
Kiyotaka Hara
SYShuwa Yagi
Shuwa Yagi
YHYoko Hirono-Hara
Yoko Hirono-Hara
HKHiroshi Kikukawa
Hiroshi Kikukawa
The valuable marine carotenoid, astaxanthin, is used in supplements, medicines and cosmetics. In this study, crustacyanin, an astaxanthin-binding protein, was used to solubilize and concentrate astaxanthin. The recombinant crustacyanin of European lobster spontaneously formed an inclusion body when it was over-expressed in Escherichia coli. In this study, fusing the NusA-tag to the crustacyanin subunits made it possible to express in a soluble fraction and solubilize astaxanthin in aqueous solution. By cutting off the NusA-tag, the crustacyanin subunits generated the pure insoluble form, and captured and concentrated astaxanthin. Overall, the attaching and releasing NusA-tag method has the potential to supply solubilized carotenoids in aqueous solution and concentrated carotenoids, respectively.

1 January 2023 in Microbiome Research Reports
Verified
Journal Article
Open access
PDF file
HKHiroshi Kikukawa
Hiroshi Kikukawa
TNToshihiro Nagao
Toshihiro Nagao
MOMitsuki Ota
Mitsuki Ota
STShigeo Takashima
Shigeo Takashima
KKKohji Kitaguchi
Kohji Kitaguchi
KHKiyotaka Y. Hara
Kiyotaka Y. Hara
Aims: C16 monounsaturated fatty acid (C16:1) show antibacterial activity against Staphylococcus aureus, a pathogen associated with various diseases such as atopic dermatitis and bacteremia, while the compound does not exhibit antibacterial activity against Staphylococcus epidermidis, an epidermal commensal that inhibits the growth of S. aureus. In this study, we aimed to find bifidobacterial strains with the ability to produce C16:1 and to find a practical manner to utilize C16:1-producing strains in industry. Methods: Various Bifidobacterium strains were screened for their content of C16:1. The chemical identity of C16:1 produced by a selected strain was analyzed by gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS). Medium components that affect the C16:1 content of the selected strain were investigated. Antibacterial activity against staphylococci was compared between the authentic C16:1 isomers and total fatty acids (TFA) extracted from the selected strain. Results: B. adolescentis 12451, B. adolescentis 12-111, B. boum JCM 1211, and Bifidobacterium sp. JCM 7042 showed high C16:1 content among the tested strains. TFA extracted from Bifidobacterium sp. JCM 7042 contained C16:1 at 2.3% as the fatty acid constituent (2.4 mg/L of broth). Through GC-MS and LC-MS analyses, the C16:1 synthesized by Bifidobacterium sp. JCM 7042 was identified as 7-cis-hexadecenoic acid (7-cis-C16:1). The authentic 7-cis-C16:1 showed strong and selective antibacterial activity against S. aureus, similar to 6-cis-C16:1, with a minimum inhibitory concentration (MIC) of < 10 µg/mL. Components that increase C16:1 productivity were not found in the MRS and TOS media; however, Tween 80 was shown to considerably reduce the C16:1 ratio in TFA. Antibacterial activity against S. aureus was observed when the TFA extracted from Bifidobacterium sp. JCM 7042 contained high level of 7-cis-C16:1 (6.1% in TFA) but not when it contained low level of 7-cis-C16:1 (0.1% in TFA). Conclusion: The fatty acid, 7-cis-C16:1, which can selectively inhibit the S. aureus growth, is accumulated in TFA of several bifidobacteria. The TFA extracted from cultured cells of Bifidobacterium sp. JCM 7042 demonstrated antibacterial activity. From a practical viewpoint, our findings are important for developing an efficient method to produce novel skin care cosmetics, functional dairy foods, and other commodities.